Evolent Health Inc (NYSE:EVH)’s traded shares stood at 0.54 million during the latest session, with the company’s beta value hitting 1.48. At the last check today, the stock’s price was $9.73, to imply a decrease of -0.56% or -$0.06 in intraday trading. The EVH share’s 52-week high remains $35.00, putting it -259.71% down since that peak but still an impressive -0.1% since price per share fell to its 52-week low of $9.74. The company has a valuation of $1.13B, with an average of 1.62 million shares in intraday trading volume over the past 10 days and average of 2.81 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Evolent Health Inc (EVH), translating to a mean rating of 1.13. Of 5 analyst(s) looking at the stock, 0 analyst(s) give EVH a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 5 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.01.
Evolent Health Inc (NYSE:EVH) trade information
After registering a -0.56% downside in the latest session, Evolent Health Inc (EVH) has traded red over the past five days. The 5-day price performance for the stock is -6.84%, and -18.60% over 30 days. With these gigs, the year-to-date price performance is -13.47%. Short interest in Evolent Health Inc (NYSE:EVH) saw shorts transact 11.29 million shares and set a 5.2 days time to cover.
The extremes give us $14 and $38 for target low and target high price respectively. As such, EVH has been trading -290.54% off suggested target high and -43.88% from its likely low.
Evolent Health Inc (EVH) estimates and forecasts
Looking at statistics comparing Evolent Health Inc share performance against respective industry, we note that the company has underperformed competitors. Evolent Health Inc (EVH) shares are -52.35% down over the last 6 months, with its year-to-date growth rate lower than industry average at -18.39% against 25.00%. The rating firms project that company’s revenue will grow 30.33% compared to the previous financial year.
Revenue forecast for the current quarter as set by 14 analysts is 651.01M. Meanwhile, for the current quarter, a total of 11 analyst(s) estimate revenue growth to 599.8M.Earnings reports from the last fiscal year show that sales brought in 556.05M and 639.65M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 17.08% before dropping -6.23% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -13.43% for the past 5-year period. While 2025 is set for a -18.60% return in earnings, projections for the next 5 years are at 0.83% annually.
EVH Dividends
Evolent Health Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Evolent Health Inc (NYSE:EVH)’s Major holders
Evolent Health Inc insiders hold 2.26% of total outstanding shares, with institutional holders owning 113.99% of the shares at 116.63% float percentage. In total, 113.99% institutions holds shares in the company, led by WELLINGTON MANAGEMENT GROUP LLP. As of 2024-06-30, the company held over 11.17 million shares (or 9.785% of shares), all amounting to roughly $213.55 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 11.06 million shares, or about 9.6862% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $211.39 million.
We also have Vanguard Specialized-Health Care Fund and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Evolent Health Inc (EVH) shares. Going by data provided on Oct 31, 2024 , Vanguard Specialized-Health Care Fund holds roughly 4.98 shares. This is just over 4.27% of the total shares, with a market valuation of $48.82 million. Data from the same date shows that the other fund manager holds a little less at 3.48, or 2.99% of the shares, all valued at about 34.17 million.
